Novel stability-indicating RP-LC method for the determination of nelfinavir mesylate and its related impurities in drug substance and pharmaceutical formulations

Journal of Liquid Chromatography and Related Technologies

Volumn 31, Issue 3, 2008, Pages 395-409

  Seshachalam, U ^a   Rajababu, B ^a   Haribabu, B ^a   Chandrasekhar, K B ^b  

^a Matrix Laboratories Limited   (India)

^b JNTUA COLLEGE OF ENGINEERING   (India)

Author keywords

Column liquid chromatography; Drug substance; Forced degradation; Impurities; Nelfinavir; Stability indicating method

Indexed keywords

ACETONITRILE; COLUMN CHROMATOGRAPHY; FLOW RATE; IMPURITIES; LIQUID CHROMATOGRAPHY; METHANOL; SODIUM COMPOUNDS;

DEGRADATION PRODUCTS; DRUG SUBSTANCE; FORCED DEGRADATION; PHARMACEUTICAL FORMULATIONS; SODIUM PHOSPHATE BUFFER; STABILITY-INDICATING METHOD;

DRUG PRODUCTS;

ACETONITRILE; BUFFER; METHANOL; NELFINAVIR; SODIUM DIHYDROGEN PHOSPHATE;

ACCURACY; ANALYTIC METHOD; ARTICLE; ASSAY; CONCENTRATION RESPONSE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG IMPURITY; DRUG STABILITY; FLOW RATE; HYDROLYSIS; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MOLECULAR STABILITY; OXIDATION; PHOTOLYSIS; QUALITY CONTROL; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 37549062651     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070701780698     Document Type: Article

References (15)

1. Yamada, H.; Kotaki, H.; Nakamura, T.; Iwamoto, A. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, and nel-finavir in human plasma by high-performance liquid chromatography. J. Chromatogr. B 2001, 755, 85-89.
2. Marzolini, C.; Telenti, A.; Buclin, T.; Biollaz, J. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J. Chromatogr. B 2000, 740, 43-58.
3. Turner, M.L.; Reed-Walker, K.; King, J.R.; Acosta, E.P. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J. Chromatogr. B 2003, 784, 331-341.
4. Dailly, E.; Thomas, L.; Kergueris, M.F.; Jolliet, P.; Bourin, M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. J. Chromatogr. B 2001, 758, 129-135.
5. Sarasa-Nacenta, M.; Lopez-Pua, Y.; Mallolas, J.; Blanco, J.L. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir, and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 2001, 757, 325-332.
6. Justesen, U.S.; Pedersen, C.; Klitgaard, N.A. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir, and the nelfinavir active metabolite M8 in plasma by liquid chromatography. J. Chromatogr. B 2003, 783, 491-500.
7. Janoly, A.; Bleyzac, N.; Favetta, P.; Gagneu, M.C. Simple and rapid highperformance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir, and saquinavir assay in plasma. J. Chromatogr. B 2002, 780, 155-160.
8. Chi, J.; Jayewardene, A.L.; Stone, J.A.; Motoya, T. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir, and amprenavir in human plasma by LC/MS/MS. J. Pharm. Biomed. Anal 2002, 30, 675-684.
9. Rentsch, K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B 2003, 788, 339-350.
10. Van Heeswijk, R.P.G.; Hoetelmans, R.M.W.; Harms, R.; Meenhorst, P.L. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 1998, 719, 159-168.
11. Kaul, N.; Agrawal, H.; Paradkar, A.R.; Mahadik, K.R. Stability indicating highperformance thin-layer chromatographic determination of nelfinavir mesylate as bulk drug and in pharmaceutical dosage form. Anal. Chim. Acta 2004, 502, 31-38.
12. Jing, Q.; Shen, Y.; Tang, Y.; Ren, F.; Yu, X.; Hou, Z. Determination of nelfinavir mesylate as bulk drug and in pharmaceutical dosage form by stability indicating HPLC. J. Pharm. Biomed. Anal. 2006, 41, 1065-1069.
13. ICH International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, "Impurities in new drug substances". 2002, Q3A(R1).
14. Inaba, T.; Birchler, A.G.; Yamada, Y.; Sagava, S.; Yokota, K.; Ando, K.; Uchida, I. A practical synthesis of nelfinavir, an HIV protease Inhibitor, using a Noval Chiral C4 building block: (5R,6S)-2,2-Dimethyl-5-hydroxy-1,3-dioxepan- 6-yl ammonium acetate. J. Org. Chem. 1998, 63, 7582-7583.
15. ICH International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, "Validation of analytical procedures". 2005, Q2(R1).